Review
Chemistry, Medicinal
Heleen Hanssens, Fien Meeus, Kim De Veirman, Karine Breckpot, Nick Devoogdt
Summary: Immuno-oncology, particularly CAR-T cell therapy, has achieved significant progress in recent years. The optimization of the CAR ectodomain, including the development of new CAR designs, has become a focus in the field. Different formats of CARs have their own advantages and disadvantages, and the optimization of various parameters plays a critical role in T cell activation.
MEDICINAL RESEARCH REVIEWS
(2022)
Article
Oncology
Loic Reppel, Ourania Tsahouridis, Jason Akulian, Ian J. Davis, Hong Lee, Giovanni Fuca, Jared Weiss, Gianpietro Dotti, Chad Pecot, Barbara Savoldo
Summary: This study suggests that GD2 is a promising target for CAR-T cell therapy in lung cancer, and the use of tazemetostat can upregulate GD2 expression in tumor cells, enhancing their susceptibility to CAR-T cell targeting.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Respiratory System
Wen Tian, Jinhui Zhao, Wenzhong Wang
Summary: The study demonstrates that CDH17 CAR-T cells exhibit potent cytotoxicity against SCLC cells in vitro with high specificity. Treatment with CDH17 CAR-T cells significantly decelerates the growth rate of SCLC-derived xenograft tumors.
Article
Oncology
A. Holzinger, H. Abken
Summary: CAR T-cell therapy modulates the quality and duration of T-cell response by adjusting the modular composition of CAR. CAR T-cells can act as biopharmaceutical factories through CAR-mediated release of transgenic therapeutic proteins. While CAR T-cell therapy has shown clinical efficacy in treating hematological malignancies, treating solid tumors poses more challenges.
Article
Medicine, General & Internal
A. Holzinger, H. Abken
Summary: The CAR technology aims to enhance selectivity and anti-tumor immunity by developing a recombinant receptor-signal molecule. Research has shown that CAR-mediated T-cell activation is influenced by factors like binding affinity, target antigen epitope, expression density, and signaling domains. The quality and duration of the T-cell response can be specifically modulated by modifying the modular composition of the CAR.
Article
Gastroenterology & Hepatology
Zhen Dai, Guangqi Song, Asha Balakrishnan, Taihua Yang, Qinggong Yuan, Selina Moebus, Anna-Carina Weiss, Martin Bentler, Jimin Zhu, Xuemei Jiang, Xizhong Shen, Heike Bantel, Elmar Jaeckel, Andreas Kispert, Arndt Vogel, Anna Saborowski, Hildegard Buening, Michael Manns, Tobias Cantz, Michael Ott, Amar Deep Sharma
Article
Chemistry, Medicinal
Ruth Rieser, Magalie Penaud-Budloo, Mohammed Bouzelha, Axel Rossi, Tim Menzen, Martin Biel, Hildegard Buening, Eduard Ayuso, Gerhard Winter, Stylianos Michalakis
JOURNAL OF PHARMACEUTICAL SCIENCES
(2020)
Editorial Material
Biotechnology & Applied Microbiology
Hildegard Buening
Article
Multidisciplinary Sciences
Marta Pradas-Juni, Nils R. Hansmeier, Jenny C. Link, Elena Schmidt, Bjork Ditlev Larsen, Paul Klemm, Nicola Meola, Hande Topel, Rute Loureiro, Ines Dhaouadi, Christoph A. Kiefer, Robin Schwarzer, Sajjad Khani, Matteo Oliverio, Motoharu Awazawa, Peter Frommolt, Joerg Heeren, Ludger Scheja, Markus Heine, Christoph Dieterich, Hildegard Buening, Ling Yang, Haiming Cao, Dario F. De Jesus, Rohit N. Kulkarni, Branko Zevnik, Simon E. Troeder, Uwe Knippschild, Peter A. Edwards, Richard G. Lee, Masayuki Yamamoto, Igor Ulitsky, Eduardo Fernandez-Rebollo, Thomas Q. de Aguiar Vallim, Jan-Wilhelm Kornfeld
NATURE COMMUNICATIONS
(2020)
Review
Immunology
Michael A. Morgan, Hildegard Buening, Martin Sauer, Axel Schambach
FRONTIERS IN IMMUNOLOGY
(2020)
Review
Oncology
Ulrich T. Hacker, Martin Bentler, Dorota Kaniowska, Michael Morgan, Hildegard Buening
Review
Biotechnology & Applied Microbiology
Esther Rodriguez-Marquez, Nadja Meumann, Hildegard Buening
Summary: Capsid engineering is a promising strategy to improve the efficacy of AAV vector system in clinical application, by reducing vector dose, lowering the risk of immune responses, and decreasing manufacturing costs.
EXPERT OPINION ON BIOLOGICAL THERAPY
(2021)
Editorial Material
Biotechnology & Applied Microbiology
Hildegard Buning, Andrew H. Baker, Uta Griesenbach, Terence R. Flotte, Adrian J. Thrasher
HUMAN GENE THERAPY
(2021)
Article
Medicine, Research & Experimental
Elisa Murenu, Marina Pavlou, Lisa Richter, Kleopatra Rapti, Sabrina Just, Jasmina Cehajic-Kapetanovic, Neda Tafrishi, Andrew Hayes, Rachel Scholey, Robert Lucas, Hildegard Buening, Dirk Grimm, Stylianos Michalakis
Summary: Inherited retinal dystrophies (IRDs) involve progressive degeneration and loss of photoreceptors, making gene supplementation therapy a promising treatment approach. However, at later disease stages when photoreceptors are lost, alternative strategies such as optogenetic tools targeting ON bipolar cells are needed. Efficient gene delivery tools for ON bipolar cells are lacking, highlighting the importance of effective cell isolation techniques like fluorescence-activated cell sorting (FACS).
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT
(2021)
Article
Medicine, Research & Experimental
Marina Pavlou, Christian Schon, Laurence M. Occelli, Axel Rossi, Nadja Meumann, Ryan F. Boyd, Joshua T. Bartoe, Jakob Siedlecki, Maximilian J. Gerhardt, Sabrina Babutzka, Jacqueline Bogedein, Johanna E. Wagner, Siegfried G. Priglinger, Martin Biel, Simon M. Petersen-Jones, Hildegard Buening, Stylianos Michalakis
Summary: A novel engineered rAAV vectors have been developed for efficient targeting of photoreceptors via less invasive intravitreal administration, showing potential for clinical application in treating blinding retinal dystrophies.
EMBO MOLECULAR MEDICINE
(2021)
Article
Biotechnology & Applied Microbiology
Manuela Voelkner, Marina Pavlou, Hildegard Buening, Stylianos Michalakis, Mike O. Karl
Summary: rAAV vectors are widely used in gene delivery in the retina, showing safety and efficacy in treating inherited retinal dystrophies with limitations in transduction efficiency. Novel variants with modified capsid sequences have been engineered to improve this efficiency. Testing on hiPSC-derived human retinal organoids showed promising results with AAV9.NN achieving the highest efficiency in transduction. Using human organoids provides a valuable platform for evaluating novel AAV vectors for gene therapy applications in the retina.
HUMAN GENE THERAPY
(2021)
Article
Genetics & Heredity
Michael Morgan, Juliane W. Schott, Axel Rossi, Christian Landgraf, Athanasia Warnecke, Hinrich Staecker, Anke Lesinski-Schiedat, Brigitte Schlegelberger, Hildegard Buening, Bernd Auber, Axel Schambach
MEDIZINISCHE GENETIK
(2020)
Meeting Abstract
Biotechnology & Applied Microbiology
Marina Pavlou, Johanna Wagner, Christian Schoen, Jackob Siedlecki, Siegfried Priglinger, Martin Biel, Hildegard Buening, Stylianos Michalakis
Article
Multidisciplinary Sciences
Simon Alexander Krooss, Zhen Dai, Florian Schmidt, Alice Rovai, Julia Fakhiri, Akshay Dhingra, Qinggong Yuan, Taihua Yang, Asha Balakrishnan, Lars Steinbrueck, Sangar Srivaratharajan, Michael Peter Manns, Axel Schambach, Dirk Grimm, Jens Bohne, Amar Deep Sharma, Hildegard Buening, Michael Ott
Review
Pharmacology & Pharmacy
Hildegard Buening, Axel Schambach, Michael Morgan, Axel Rossi, Helena Wichova, Hinrich Staecker, Athanasia Warnecke, Thomas Lenarz
EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT
(2020)
